Back
MigVax-101
Ukrainian
MigVax-101
Vaccine candidate against COVID-19
MigVax-101
Vaccine description
Target
SARS-CoV-2
Vaccine type
Virus-like particles
Clinical data
Routes of
administration
Oral
Part of
a series
on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
COVID-19
(disease)
SARS-CoV-2
(virus)
Cases
Deaths
Timeline
2019
2020
January
responses
February
responses
March
responses
April
responses
May
responses
June
responses
July
responses
August
responses
September
responses
October
responses
November
responses
December
responses
2021
January
responses
February
responses
March
responses
April
responses
May
responses
June
responses
July
responses
August
responses
September
responses
October
responses
November
responses
December
responses
2022
January
responses
February
responses
March
responses
April
responses
May
responses
June
responses
July
responses
August
responses
September
responses
October
responses
November
December
2023
Locations
By country and territory
Africa
Antarctica
Asia
Europe
North America
Oceania
South America
By conveyance
Cruise ships
Naval ships
International response
Endemic phase
Evacuations
Face masks
International aid
Origin
Lockdowns
by country
Misinformation
by governments
Fake treatments
Social distancing
Software
Travel
United Nations
World Health Organization
WTO IP waiver
Undercounting of deaths
COVID-19 apps
Zero-COVID
National responses
Africa
China
European Union
Germany
Ghana
India
Ireland
Netherlands
New Zealand
Nigeria
Philippines
Russia
Sweden
UK
government
US
federal government
Vietnam
Medical response
Disease testing
Breathalyzer
Development
Drug development
Drug repurposing
Public health mitigation
Vaccines
History
Research
VITT
Deployment
Authorizations
Operation Warp Speed
Misinformation and hesitancy
US
Vaccine card
Vaccine passports
Current vaccines
CoronaVac
Covaxin
Convidecia
Janssen
Medigen
Moderna
Novavax
Oxford–AstraZeneca
Pfizer–BioNTech
Sinopharm BIBP
Sputnik V
Variants
Variants of concern
Alpha
Beta
Gamma
Delta
Omicron
Other variants
Epsilon
Zeta
Eta
Theta
Iota
Kappa
Lambda
Mu
Cluster 5
Lineage B.1.617
Economic impact
and
recession
Arts and culture
Aviation
Cannabis
Cinema
films
Disney
Fashion
Financial markets
Food industry
Food security
Journalism
Music
Performing arts
Retail
Shipping
Television
US
sportscasting
programs
Tourism
Video games
By country
Canada
India
Ireland
Malaysia
New Zealand
Russia
UK
US
By sport
Association football
Baseball
Basketball
Combat sports
Cricket
Disc golf
Gaelic games
Gridiron football
Ice hockey
Motorsport
Rugby league
Impacts
Long COVID
Neurological and psychological symptoms
Post-exertional malaise
Society
Animals
Alzheimer's disease patients
Black people
Crime
Death rates by country
Disability
Domestic violence
Emergency evacuations
Education
Female
Environment
Hospitals
Language
LGBT community
Long-term care
Media coverage
Mental health
Migration
Military
Notable deaths
Other health issues
Popular culture
Protests
Pregnancy
Prisons
Religion
Catholic Church
Hajj
Science and technology
Social media
Strikes
Suicides
Telehealth
Xenophobia and racism
Politics
Diplomacy
Ireland
Malaysia
New Zealand
Russia
UK
US
COVID-19 portal
v
t
e
MigVax-101
is a
COVID-19 vaccine
candidate developed by Oravax Medical.
[
1
]
[
2
]
[
3
]
^
Jaffe-Hoffman M (11 June 2021).
"Israeli oral COVID-19 vaccine en route to clinical trials"
. The Jerusalem Post
. Retrieved
2 November
2021
.
^
Jaffe-Hoffman M (22 July 2021).
"Israel to become first in world to test Oravax oral COVID-19 vaccine"
. The Jerusalem Post
. Retrieved
2 November
2021
.
^
"Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial"
. Cision PR News Wire. 29 October 2021
. Retrieved
2 November
2021
.
From
Wikipedia
, the free encyclopedia · View on
Wikipedia
Developed by
Tubidy